Relapse Clinical Trial
Official title:
Autologous Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia After Relapse With Idarubicin and Busulfan Conditioning
For relapsed acute promyelocytic leukemia after all-trans retinoic acid (ATRA) and arsenic treatment, remission can be achieved by chemotherapy with ATRA and/or arsenic and addition of mylotarg. Autologous hematopoietic cell transplantation using a polymerase chain reaction (PCR) negative graft is important treatment option to obtain sustainable remission. This study is to test the efficacy and the safety of conditioning regimen with idarubicin and busulfan for relapsed Acute Promyelocytic Leukemia (APL).
Once relapsed acute promyelocytic leukemia achieved molecular remission after all-trans
retinoic acid (ATRA) and arsenic treatment, PBSC was mobilized and collected with further
confirmation of molecular remission via RT-PCR.
Patients received autologous hematopoietic cell transplantation.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
| Completed |
NCT00306813 -
Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1/Phase 2 | |
| Completed |
NCT01956695 -
Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma
|
Phase 2 | |
| Not yet recruiting |
NCT05926167 -
Observational Trial Evaluating Elevated Factor VIII Related Labs as a Biomarker for Incomplete Relapse Recovery
|
||
| Recruiting |
NCT03710512 -
Evaluation of Early Relapse After Mandibular Lengthening Surgery
|
||
| Recruiting |
NCT04921540 -
Ingrown Toenails : Surgery Only Versus Surgery + Chemical Cauterization With TCA
|
N/A | |
| Not yet recruiting |
NCT03830827 -
MBRP + Vortioxetine VS MBRP on Preventing Relapse in Chronic MA Users
|
Phase 4 | |
| Completed |
NCT05250765 -
Comparison of Efficiency and Effectiveness of Two Types of Bonded Orthodontic Retainers: an RCT.
|
N/A | |
| Completed |
NCT05915273 -
Relapse and Failure Rates Between CAD/CAM and Conventional Fixed Retainers
|
N/A | |
| Active, not recruiting |
NCT04389879 -
CAD/CAM Fixed Retainers vs. Conventional Multistranded Fixed Retainers in Orthodontic Patients. Comparison of Stability, Retainer Failure Rate, Adverse Effects, Cost-effectiveness, and Patient Satisfaction. A Randomized Controlled Clinical Trial
|
N/A | |
| Recruiting |
NCT06417359 -
Comparison of Mesh Fixation and Non-Fixation in eTEP
|
N/A | |
| Recruiting |
NCT06417346 -
Comparison of Laparoscopic and Open Inguinal Hernia Repair in Elderly Patients
|
N/A | |
| Completed |
NCT02145403 -
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT01481701 -
A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma
|
Phase 2 | |
| Recruiting |
NCT01941394 -
Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation
|
Phase 2 | |
| Recruiting |
NCT04723901 -
Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT04994626 -
Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies
|
Phase 2 | |
| Recruiting |
NCT06292364 -
Comparison of Retention Characteristics of Immediate vs Delayed Retainer Delivery Using 3D Digital Model Analysis
|
N/A | |
| Enrolling by invitation |
NCT05591703 -
Clinical Outcomes Following Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention: A Long-term Follow-up Study
|
||
| Active, not recruiting |
NCT00299923 -
Study for Patients With Chronic HCV (GT 1 or 3) Who Relapsed to Previous (Peg)Interferon/ Ribavirin Combination Therapy
|
Phase 3 |